Opus Genetics今日重磅披露——其核心在研疗法Opgx-Best1在1/2期临床试验低剂量队列1中斩获积极数据，这一里程碑式的进展为后续开发铺平了道路。与此同时，公司与美国食品药品监督管理局（FDA）召开的C类会议也以圆满收官告捷。种种迹象表明，该项目若顺利推进，2027年或将迎来关键的3期临床给药阶段。
在试验中，低剂量队列1的数据让人眼前一亮，安全性和耐受性表现均符合预期。这一积极信号不仅验证了药物的初始潜力，也为更高剂量组的探索注入了一剂强心针。更值得关注的是，FDA的C类会议反馈为产品的监管路径提供了清晰指引——双方就后续开发策略达成共识，扫清了研发征途上的重要障碍。
从时间表来看，潜在的第3期试验给药窗口有望锁定在2027年。这意味着，Opus Genetics正在以扎实的步伐，将这一基因疗法候选药物从实验室推向临床应用的快车道。该公司在遗传性视网膜疾病领域的深耕，如今正收获阶段性硕果。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.